PaxMedica cancels all outstanding shares, deregisters with SEC

PaxMedica, Inc.

Company changed name to Kuvatris Therapeutics; all outstanding shares declared null, void, and worthless.
Shares held by DTC and record shareholders ordered cancelled; beneficial shareholders left with worthless equity.
Company to file Form 15-12g terminating SEC registration, ending all reporting obligations under Exchange Act.
CEO Howard Weisman executed name change on June 6, 2025; share cancellation letter sent to DTC on May 20.

item 5.03item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.